Publication Name	World Journal of Meta-Analysis
Manuscript ID	47569
Country	United Arab Emirates

Received	2019-03-17 07:41
Peer-Review Started	2019-03-18 00:09
To Make the First Decision	2019-04-17 05:29
Return for Revision	2019-04-17 09:22
Revised	2019-04-21 04:34
Second Decision	2019-04-22 10:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-04-23 04:24
Articles in Press	2019-04-23 04:24
Publication Fee Transferred
Edit the Manuscript by Language Editor	2019-04-25 22:09
Typeset the Manuscript	2019-04-29 07:01
Publish the Manuscript Online	2019-04-30 03:02

ISSN	2308-3840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Minireviews
Article Title	Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump
Manuscript Source	Unsolicited Manuscript
All Author List	Naina Mohamed Pakkir Maideen
Funding Agency and Grant Number
Corresponding Author	Naina Mohamed Pakkir Maideen, PhD, Doctor, Pharmacist, Department of Pharmacy, Dubai Health Authority, Al Maktoum Bridge Street, Dubai 4545, United Arab Emirates. nmmaideen@dha.gov.ae
Key Words	Drug interactions; Sitagliptin; Saxagliptin; Linagliptin; Gemigliptin; Teneligliptin; Vildagliptin; Anagliptin; CYP3A4; P-gp efflux pump
Core Tip	The probability of adverse drug interactions is higher among Diabetic patients due to the concomitant administration of antidiabetic drugs with multiple medications to treat comorbidities such as hypertension, dyslipidemia, other cardiovascular problems, infections, depression, and others. Dipeptidyl peptidase 4 (DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus. Some of the DPP4 inhibitors have been identified as the substrates of CYP3A4/5 enzymes and P-gp efflux pump. The drugs inhibiting or inducing CYP3A4/5 enzymes and/or P-gp can alter the pharmacokinetics of DPP4 inhibitors. The prescribers and the pharmacists are required to be aware of the drugs altering the pharmacokinetics of DPP4 inhibitors significantly, to prevent adverse drug interactions.
Publish Date	2019-04-30 03:02
Citation	Maideen NMP. Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World J Meta-Anal 2019; 7(4): 156-161
URL	https://www.wjgnet.com/2308-3840/full/v7/i4/156.htm
DOI	https://dx.doi.org/10.13105/wjma.v7.i4.156

Full Article (PDF)	WJMA-7-156.pdf
Full Article (Word)	WJMA-7-156.docx
Manuscript File	FP6834_de16_CE1MS_edit2.docx
Answering Reviewers	47569-Answering reviewers.pdf
Audio Core Tip	47569-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	47569-Conflict-of-interest statement.pdf
Copyright License Agreement	47569-Copyright license agreement.pdf
Peer-review Report	47569-Peer-review(s).pdf
Scientific Misconduct Check	47569-Scientific misconduct check.pdf
Scientific Editor Work List	47569-Scientific editor work list.pdf